Trial Profile
Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 26 Oct 2020
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Itraconazole (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 20 Oct 2020 Planned initiation date changed from 1 Sep 2019 to 1 Dec 2020.
- 20 Oct 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Apr 2019 Planned End Date changed from 1 Nov 2019 to 1 Sep 2021.